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Available online 10 November 2016Objective:Microparticles (MPs) aremembrane-bound vesicles derived from vascular and intravascular cells such
as endothelial cells (EMPs) and platelets (PMPs). We investigated EMP and PMP numbers across a spectrum of
autoimmune rheumatic diseases (AIRDs) with the aim of comparing the levels of, and relationship between,
EMPs and PMPs.
Methods: Patientswith Systemic Lupus Erythematosus (SLE) (n=24), Systemic Sclerosis (SSc) (n=24), Primary
Raynauds Phenomenon (RP) (n= 17) and “other CTD” (n= 15) (Primary Sjogrens Syndrome, UCTD or MCTD)
aswell as 15 healthy controlswere recruited. EMPs and PMPswere quantiﬁedusing ﬂow cytometry. Associations
between MP levels and objective functional vascular assessments were evaluated.
Results: SLE patients had signiﬁcantly higher EMPs comparedwith healthy controls and SSc patients. Higher PMP
levels were noted in SSc and primary RP when compared to healthy controls and ‘other CTD’ patients. A modest
correlation was noted between EMP and PMP levels in healthy controls (Spearman r = 0.6, p = 0.017). This
relationship appeared stronger in SLE (r = 0.72, p b 0.0001) and other CTD patients (r = 0.75, p b 0.0001).
The association between EMPs and PMPs was notably less strong in SSc (r = 0.45, p = 0.014) and RP (r =
0.37, p = 0.15). A signiﬁcantly lower EMP/PMP ratio was detected in SSc/RP patients in comparison to both
healthy controls and SLE/other CTDpatients. Higher EMP and PMP levelswere associatedwith higher digital per-
fusion following cold challenge in SSc. In contrast, higher PMP (but not EMP) levels were associated with lower
digital perfusion at both baseline and following cold challenge in primary RP. Higher PMP levels were associated
with greater endothelial-independent dilation in patients with SLE.
Conclusion:MPpopulations differ across the spectrum of AIRDS, possibly reﬂecting differences in vascular cell in-
jury and activation. MP levels are associated with functional assessments of vascular function and might have a
role as novel vascular biomarkers in AIRDs.
Signiﬁcance and innovations: Levels of circulating endothelial and platelet microparticles differ between SSc/pri-
mary RP compared with SLE and other CTDs (UCTD, MCTD and Primary Sjogrens). MP release may occur within
different vascular sites across these disease groups (macrovascular and microvascular).
The association between circulatingMP levels and objective assessment ofmacro- andmicrovascular dysfunction
within these disease areas suggests that MPsmight have a useful role as novel circulating biomarkers of vascular
disease within the CTDs.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Endothelial microparticles
Platelets
Systemic lupus erythematosus
Systemic sclerosisal Research, The University of
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. Parker).
pen access article under the CC BY-N1. Introduction
Microparticles (MPs) are membrane-bound vesicles that display bi-
ological activities which impact on normal physiology as well as the
pathogenesis of immune-mediated diseases [1].MPs arise from cells un-
dergoing activation or apoptosis, detaching from the membrane asC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cross-talk in the regulation of inﬂammation, vascular function, cell apo-
ptosis and proliferation. Thus MPs might contribute to the immuno-
pathogenesis of various diseases via their role in the regulation of
inﬂammation, thrombosis and angiogenesis [2]. High MP levels have
been reported in diseases associatedwith vascular damage, such as ath-
erosclerosis and coronary artery disease, whilst low levels have been
observed in sepsis. This suggests diverse effects of MPs across a spec-
trum of disease, which may be in part, dependent on the disease and/
or stimulus they encounter [3,4]. MP phenotype has also been demon-
strated to be transformed depending on the underlying disease and pa-
tient population. For example in chronic heart failure (CHF) body mass
index has been demonstrated to be a signiﬁcant predictor for impaired
phenotype of circulating endothelial microparticles (EMPs) in patients
[5,6]. Similarly development of CHF in metabolic syndrome patients
may be closely related to altered balance between activated endothelial
cell-derived MPs and apoptotic endothelial cell-derived MPs. This phe-
nomenon of impaired phenotype of circulatingMPs has been suggested
as a precursor to both clinically signiﬁcant endothelial dysfunction and
resultant CHF [5,6]. Studies in patients with a wide variety of rheumatic
diseases have generally reported elevation in MP numbers compared
with healthy control populations. These elevations are most notable in
conditions with a strong vascular component and primarily involve
platelet MPs (PMPs), with elevations of EMPs having also been docu-
mented [7–9].
The pathological hallmark of Systemic Sclerosis (SSc) is microvascu-
lar injury, leading to ischaemia and tissue remodelling (ﬁbrosis). Endo-
thelial cell activation is one of the potential pathological mechanisms in
SSc [10]. Platelets have long been considered a potentially important
cell mediator in the pathogenesis of SSc and release a large number of
vasoactive mediators (e.g. thromboxane, serotonin) and growth factors
(TGF-β, PDGF) that might contribute to tissue ischaemia and remodel-
lingﬁbrosis [11]. However, the precursormolecularmechanismsunder-
lying disease remain ill-deﬁned and the contribution of EMPs and PMPs
to disease remains unclear. Previous studies describing MP levels in SSc
have reported conﬂicting results [7,12].
Systemic Lupus Erythematosus (SLE) is associated with features of
macrovascular disease such as atherosclerosis, attributable in part, to
chronic systemic inﬂammation. Aswith SSc, the function ofMPs derived
from speciﬁc tissues or cells in SLE remains unclear. Most studies have
foundelevatednumbers of circulatingMPs in SLE patients [13,14]. How-
ever, others have reported either unchanged or lower levels of total and
PMPs [9]. Previously we have demonstrated that EMP levels are related
tomeasures of vascular damage and endothelial dysfunction in patients
with active SLE [15].
Few studies have evaluated EMP and PMP levels across a spectrum
of connective tissue diseases. Such datamay help delineate their contri-
bution to disease pathogenesis in addition to providing an attractive cir-
culating biomarker of vascular injury and disease activity. The principal
objectives of this study were to evaluate EMP and PMP levels across a
spectrum of connective tissue diseases, with known varying degrees
of macrovascular and microvascular involvement. Where possible, we
have explored and shall report associations between EMP and PMP
levels with objective assessment of macro- and microvascular function.
2. Patients and methods
Patients with SLE were recruited from The Kellgren Centre for
Rheumatology, Central Manchester NHS Foundation Trust (CMFT) and
East Lancashire Hospitals NHS Trust. Although originally recruited for
a complementary study, an additional cohort of patients, deﬁnedwithin
the manuscript as “other CTD” were also recruited from CMFT. Other
CTD is deﬁned as: Primary Sjogrens Syndrome, Undifferentiated
Connective Disease or Mixed Connective tissue disease (without
features of SSc/SLE). Healthy controlswere recruited from TheUniversi-
ty ofManchester andCMFT. Patients agedbetween18 and75 yearswithSSc or primary RP were approached for inclusion in the study from the
Department of Rheumatology, Royal National Hospital for Rheumatic
Diseases, Bath. Patients with SSc fulﬁlled either the American
Rheumatology Association (ARA) and/or the LeRoy andMedsger classi-
ﬁcation criteria for early SSc. Primary RP was deﬁned as at least 2 epi-
sodes of ﬁngertip localized notable blue and/or sequential white/blue
discoloration, in conjunction with pain upon cold exposure or emotional
stress within one week of examination and anti-nuclear autoantibody
titre ≤1/160 on HEp-2 cell immunoﬂuorescence. We excluded
subjects with a recent acute infection (b1 month), recent cardiovascular
event (b3 months), any chronic infection, pregnancy and patients with
chronic kidney disease (Fig. 1). In addition SSc/RP patientswere excluded
from the study if they were taking an endothelial receptor antagonist or
anticoagulant.
All participants provided informedwritten consent and the study re-
ceived prior approval from the relevant institutional ethics review
boards.
2.1. Clinical assessment
Participants underwent history and exam at the time of study visit.
Clinical features of disease andmedication use, were recorded for all pa-
tients. All subjects were asked to abstain from smoking on the day of
study.
2.2. Additional vascular measures
Flow mediated dilatation (FMD) of the brachial artery was per-
formed using B mode ultrasound and automated edge-tracking soft-
ware in SLE patients only [15]. Peripheral microvascular perfusion was
evaluated only in SSc and primary RP by measuring digital perfusion
at the volar aspect of the distal left middle ﬁnger using Laser Speckled
Contrast Imaging (LSCI). Digital perfusion was assessed at baseline
(B), immediately following (t0) a cold challenge (hands submerged in
waterbath at 15 °C for 1 min) and at 5 min intervals during reperfusion
(t5, t10 and t15 respectively) as previously reported [16].
2.3. Assessment of endothelial and platelet microparticle levels
2.3.1. Sample collection
Peripheral venous bloodwas collected from the study participants in
a 5 ml citrated vacutainer. Platelet-poor plasma (PPP) was generated
using a two-step centrifugation process. The venous sample was initial-
ly centrifuged at 1700g for 10min at 4 °C to generate plasmawhichwas
harvested and centrifuged at 20,000g for a further 10 min at 4 °C. The
PPP was harvested and the ﬁnal sample frozen in 100 μl aliquots at
−80 °C until analysis at a central site.
2.3.2. Flow cytometry
Sizing beads of 0.16 μM, 0.2 μM, 0.24 μM and 0.5 μM (Megamix-Plus
SSC, Stago, Marseille) were used to prepare the assay, with the thresh-
old being set on SSC as recommended by the manufacturer, for
maximum accuracy to detect MPs in the size range of 0.1 μM–1 μM.
Following appropriate control staining and compensation adjustment
EMPs and PMPs were enumerated. We added 50 μl of PPP and 50 μl
of 10 μm diameter counting beads (Flow Count Fluorospheres; Beckman
Coulter, UK), used to count a standard number of events, to 900 μl of
calcium-rich buffer (Annexin V Apoptosis Detection Kit, BD Pharmingen,
UK 556547). Simultaneous incubation for 15 min with ﬂuorescent
antibodies was performed using 2.5 μl of phycoerythrin (PE)-conjugated
antihuman CD31 (BD Pharmingen 55546), 2.5 μl of allophycocyanin
(APC)-conjugated anti-human CD42b (BD Pharmingen 551061) and
5 μl of ﬂuorescein isothiocyanate (FITC)-conjugated anti-human
annexin-V marker (BD Pharmingen 51-65874X). Flow cytometry was
performed on prepared samples using a FACSVerse ﬂow cytometer (BD
Biosciences). Analysis was stopped once 1000 counting beads had been
Fig. 1. Flow chart of patient recruitment and exclusion criteria.
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and PMP counts permilliliter of plasmawere then calculated. The formula
for calculation of the MP levels is as follows:
V ¼ z= x=yð Þ=20
where z = total volume of sample (1000 μl); x = total number beads
added (50 × number of beads per μl); y = number of beads counted
(1000); and 20 is the dilution factor. Once the volume of plasma analysed
is known, the total number of dual positive events (AnnexinV+/CD31+/
CD42b−) is multiplied by (1000/v) to generate a number of EMPs (or
PMPs) per 1000 μl of plasma. Events positive for Annexin V (microparticleTable 1
Baseline demographics, disease characteristics and medication use in each group.
Control SLE
No. of participants 15 24
Gender
Female 14 (93.3) 23 (95.8)
Male 1 (6.7) 1 (4.2)
Age (years), mean (SD) 40.7 (10.7) 43.8 (13.1)
Disease duration 8.68 (7.3)
Smoker 14 (93.3) 21 (87.5)
No 1 (6.7) 3 (12.5)
Yes
Medication use
Oral corticosteroid 23 (95.8)
Anti-malarial 17 (70.8)
Additional immun. 11 (45.8)
Anti-platelet 7 (29.1)
Disease features ACR criteria O
Malar 16 (66.7)
Discoid 12 (50)
Ulcer 16 (66.7)
Serositis 7 (29.2) Te
Arthritis 19 (79.2)
Photosensitivity 18 (75)
Renal 10 (41.7)
CNS 6 (25)
Immunological 11 (45.8)
Raynauds 14 (58.3) R
Unless otherwise stated, values are n (%). UCTD = Undifferentiated Connective Tissue Disease
CNS=Central Nervous System. Additional Immun.=Additional Immunosuppressive therapy.
Arterial Hypertension.marker) and CD31 (endothelial marker) and negative for CD42b (plate-
let-marker) (Annexin V+/CD31+/CD42b−) were deﬁned as EMPs.
PMPs were deﬁned as the sum of Annexin V+/CD31+/CD42b+ or
Annexin V+/CD31−/CD42b+ events.2.4. Statistical analysis
Signiﬁcance of between group differences was assessed using the
Mann-Whitney U test for continuous variables and chi-squared test
for categorical variables. Non-parametric data is presented as median
(Interquartile Range (IQR)). Correlation between measures wasSystemic sclerosis Primary Raynauds Other CTD
24 17 15
lcSSc = 2 Primary Sjogrens = 6 (40)
dcSSc = 2 UCTD = 5 (33.3)
MCTD = 4 (26.7)
19 (79.1) 13 (76.5) 15 (100)
5 (20.8) 4 (23.5) 0
60.5 (8.9) 50.4 (14.1) 45.1 (12.5)
6.86 (6.6) 26.4 (16.36)
21 (87.5 ) 16 (94.1) 14 (93.3)
3 (12.5) 1 (5.9) 1 (6.7)
5 (20.8)
0 (0) 8 (52.3)
6 (25) 3 (20)
5 (20.8)
rgan involvement Organ involvement
DU or DP 12 (50) Arthritis 9 (60)
ILD 5 (20.8) Skin 6 (40)
PAH 2 (8.3) Sicca 5 (33.3)
langiectasia 18 (75)
Calcinosis 9 (37.5)
aynaud's 24 (100) Raynauds 17 (100) Raynauds 5 (33.3)
. MCTD = Mixed Connective Tissue Disease. ACR = American College of Rheumatology.
DU=Digital Ulcer. DP=Digital Pitting. ILD= Interstitial Lung Disease. PAH=Pulmonary
19E.M. McCarthy et al. / BBA Clinical 7 (2017) 16–22assessed using Spearman's correlation coefﬁcient. Data analyses were
performed using the Prism and SPSS 21.0 software packages.
3. Results
3.1. Patient Populations
Twenty-four patients with SLE and SSc, seventeen with primary RP,
ﬁfteenwith ‘other CTD’ andﬁfteen healthy controlswere enrolled. Base-
line characteristics of cases and controls are described in Table 1. Pa-
tients with SSc were signiﬁcantly older than patients with SLE, other
CTD and healthy controls (p b 0.001). No differences in terms of age
were observed between healthy controls, SLE, RP or other CTD patients.
Corticosteroids, antimalarials and additional immunosuppressive thera-
pies were usedmore frequently in the SLE groupwhen compared to the
other groups. The frequency of speciﬁc disease features in each of the
cohorts is recorded in Table 1.
3.2. Relationship between microparticle levels and disease
3.2.1. Elevated levels of EMPs in SLE
Patients with SLE had signiﬁcantly higher EMPs compared with
healthy controls [median (IQR) 293,889/ml (118,024, 797,734) vs
132,171/ml (55,426, 195,349), p= 0.03] and patients with SSc [median
(IQR) 293,889/ml (118,024, 797,734) vs 161,271/ml (111,732, 199,346),
p= 0.04]. No other differences were observed in EMP levels across the
patient groups investigated (Fig. 2A).
3.2.2. PMPs are elevated in SSc and primary RP
Signiﬁcantly higher PMP levels were noted in SSc (median (IQR)
186,348/ml (103,025, 486,144)) compared with healthy controls (me-
dian (IQR) 41,085/ml (25,969, 74,806), p b 0.001) and patients with
“Other CTD” (median (IQR) 58,178/ml (16,528, 142,296), p b 0.001).
Similarly, higher PMP levelswere noted in the primary RP compared
to healthy controls [median (IQR) 246,758/ml (161,822, 339,580) vs
41,085/ml (25,969, 74,806), p b 0.001] and patients with “other CTD”Fig. 2. The levels of EMPs and PMPs in SLE, Primary Raynauds, Systemic Sclerosis and other
CTD patients. (A) The number of EMPs/ml (Annexin V+/CD31+/CD42b− events) and
(B) PMPs/ml (Annexin V+/CD31+/CD42b+ or Annexin V+/CD31−/CD42b+ events)
were assessed by ﬂow cytometry in SLE (n = 24), SSc (n = 24), Primary Raynauds
(n = 17), other CTD patients (n = 15) as well as healthy controls (n = 15). * =
p b 0.05, ** = p b 0.01, *** = p b 0.001.[median (IQR) 246,758/ml (161,822, 339,580) vs 58,178/ml (16,528,
142,296), p b 0.001).
No signiﬁcant differences were observed in PMP levels between
SLE patients and those with either SSc or primary RP; nor was any
difference detected between the SSc and primary RP groups
(Fig. 2B). SLE patient PMP levels were not higher than healthy con-
trol PMP levels [median (IQR) 78,410 (23,246, 395,859) vs 41,085/
ml (25,969, 74,806), p = 0.12].
3.2.3. The association of microparticles with disease-related features
SLE patients with active serositis had higher EMP levels than those
without serositis [median (IQR) 808,839/ml (310,933, 1,210,000) vs
225,194/ml (100,000, 416,816), p = 0.04). No difference in EMP or
PMP numbers were observed for disease manifestations explored with-
in the “Other CTD” group. SSc patients with a history of digital ulcera-
tion/pitting (n = 12) had higher EMP levels (198,643/ml vs 144,840/
ml, p = 0.03). No additional disease associations between MP levels
and disease characteristics were identiﬁed in SSc patients.
3.2.4. The EMP/PMP ratio distinguishes Primary Raynauds phenomenon
and Systemic Sclerosis from healthy controls, SLE and other CTD patients
Next, we sought to investigate the relationship between EMPs and
PMPs. A modest correlation was noted between EMP and PMP levels
in health (Spearman r = 0.6, p = 0.017). The relationship between
EMPs and PMPs was stronger in SLE (r = 0.72, p b 0.0001) and other
CTD patients (r=0.75, p b 0.0001). In contrast, the association between
EMPs andPMPswas less strong in SSc (r=0.45, p=0.014) andprimary
RP (r= 0.37, p= 0.15).
When the EMP/PMP ratio was assessed across all groups, we noted
that the ratio of EMPs/PMPs was 2.83 in healthy controls, which was
comparable to the SLE and other CTD groups (2.83 vs 2.24 vs 3.4, p =
0.55). A signiﬁcantly lower EMP/PMP ratio was seen in both Primary
RP and SSc patients, in comparison to both healthy controls and SLE/
other CTD patients (RP= 0.64, SSc= 0.88, p b 0.01 vs healthy controls)
(Fig. 3).
3.3. Association between MP levels and objective assessments of vascular
function
3.3.1. Relationship betweenMP levels andmeasures of large vessel vascular
function in SLE
Wehave previously reported on the relationship between endothelial
function as assessed by FMD and EMPs in SLE patients [15]. Therefore, we
sought to extend these studies and investigate the relationship between
PMP levels and endothelial function in the same cohort of SLE patients.
Baseline PMP levels showed a moderate correlation with endothelium-Fig. 3. The EMP/PMP ratio distinguishes SLE fromhealthy controls, Primary Raynauds, and
Systemic Sclerosis. The ratio of EMPs/ml (Annexin V+/CD31+/CD42b− events) to
PMPs/ml (Annexin V+/CD31+/CD42b+ or Annexin V+/CD31−/CD42b+ events)
was calculated following ﬂow cytometry in SLE (n = 24), SSc (n = 24), Primary
Raynauds (n = 17), other CTD patients (n = 15) as well as healthy controls (n = 15).
* = p b 0.05, ** = p b 0.01, *** = p b 0.001.
20 E.M. McCarthy et al. / BBA Clinical 7 (2017) 16–22independent vasodilation (Spearman r= 0.56, p= 0.06), which reﬂects
vascular smooth muscle function. No association was observed between
PMP levels and FMD.
3.3.2. Relationship betweenMP levels and digitalmicrovascular response to
cold challenge assessed using LSCI in patients with primary RP and SSc
Next, we sought to investigate the relationship of EMPs and PMPs
with measures of digital perfusion in both SSc and primary RP. Consis-
tent positive correlations between both EMP and PMP levels and digital
perfusion following cold challenge (but not at baseline) were identiﬁed
in patients with SSc (Table 2). These ﬁndings suggest that higher MP
levels are associated with better digital perfusion. In contrast, there
were consistent negative correlations between PMP (but not EMP)
levels and digital perfusion at both baseline and following cold chal-
lenge in primary RP suggesting that the production of PMPs was associ-
ated with lower digital perfusion.
4. Discussion
In this study, we report different levels of EMPs and PMPs across a
spectrum of AIRDs. SLE patients have higher levels of EMPs than healthy
controls and SSc patients. In contrast, both SSc and primary RP are associ-
ated with elevated PMP levels. The EMP/PMP ratio appears to distinguish
patients with SSc/primary RP from thosewith SLE, other CTD and healthy
controls. In addition, we have identiﬁed that measurement of EMPs and
PMPs reﬂects vascular function/perfusion across disease, suggesting that
MPs may have a role as circulating markers of vascular health.
Microparticles are increasingly recognised as contributing to the
pathogenesis of awide spectrumof disease, although their precise func-
tion remains to be elucidated. Here we report that higher EMP/PMP
levels appear to differentiate SLE/other CTD from SSc/primary RP, sug-
gesting that this ratio is a potential novel biomarker to help inform cli-
nicians as to the potential evolution of undifferentiated connective
tissue disease. Whilst this may reﬂect the higher inﬂammatory burden
observed in SLE, the inclusion of an additional other CTD cohort, onmin-
imal immunosuppression, suggests an effect beyond disease activity.
Work is currently ongoingwithin our group aimed at following a cohort
of uCTD patients longitudinally to further investigate this observation.
The relationship between EMPs and PMPs appears dysregulated
across the diseases assessed. Both SLE and SSC/primary RP are
characterised by differing degrees of macrovascular and microvascular
complications respectively. Thus differences in the observed numbers
of MPs between groups, in particular SLE patients having higher EMP
numbers with SSc patients having high PMPs, may reﬂect the involve-
ment of different vascular beds and/or differential activation of plate-
lets. In addition, factors which affect the health of the vascular bed
may contribute to the observed differences. Chronic exposure to oxida-
tive stress in microvascular endothelial beds may result in the gradual
exhaustion of antioxidant protective mechanisms and destruction of
the tissue bed, thus preventing the release of potentially protective
EMPs. In support of this, Bartoloni et al. have recently demonstrated aTable 2
Correlation of EMPs and PMPs with cold challenge and reperfusion in Systemic Sclerosis and P
Baseline
SSc EMPs Spearman r 0.05
p value 0.82
PMPs Spearman r 0.19
p value 0.38
Primary RP EMPs Spearman r −0.34
p value 0.15
PMPs Spearman r −0.52
p value 0.04
Small vessel vascular perfusion in SSc and primary RP patients was assessed by digital perfusio
(LSCI) during a standardised local cold challenge (15 °C for 60 s). Digital perfusion was assesse
perfusion (t5, t10 and t15 respectively).reduction in the number of potentially reparative circulating endotheli-
al progenitor cells as disease progresses in primary Sjogrens Syndrome
[8]. Similarly EMP numbers were not elevated in our SSc cohort thus
leaving potentially harmful PMPs to exert their function unopposed. In
addition, high shear stress like that observed in the microvasculature,
has been demonstrated to increase PMP release, an effect that is further
enhanced with prolonged duration of stress [17]. It is increasingly
recognised that EMP function is more nuanced than previously consid-
ered, and themicro-environment stimulating EMP release appears to be
a key contributor to the functional properties exhibited by EMPs [18]. In
particular, the insult or injury that results in EMP release, namely cell
apoptosis or activation, results in EMPs having distinctive and differing
roles in disease, as highlighted by Jimenez et al.. [19]. Proteomic analysis
of cell-culture derived EMPs has shown that one third of the proteins
found on EMPs are speciﬁc to the stimulus initiating their release, not
only demonstrating the plasticity of these vesicles but also revealing
the complexity of the mechanisms governing their formation [20].
Taken together, these ﬁndings suggest that there are distinct mecha-
nisms for the formation of EMPs in apoptotic and activated cells [21],
with several studies suggesting that these types of EMPs have different
functions in vascular diseases potentially explaining the different EMP/
PMP ratios seen across the diseases in our study [22,23]. Thus, differ-
ences in vascular territories, conditions that stimulate EMP and PMP re-
lease and varying EMP/PMP phenotype may account for some of the
differences observed in the EMP/PMP relationship between SLE/other
CTDand SSC/RP patients, suggesting that this ratio is amarker of disease
evolution and the health of the vasculature bed territories involved in
disease.
In support of this, we have also demonstrated that measurement of
EMPs and PMPs may reﬂect the health of a patient's vasculature. PMP
levels correlate moderately with endothelium independent vasodila-
tion in SLE, reﬂecting vascular smooth muscle tone, adding to previous
work by our group, which highlighted a relationship between EMPs
and endothelial vascular function [15]. Similarly, we have identiﬁed
that EMPs and PMPs reﬂect digital perfusion following localized cold
challenge in SSc. Of note whilst PMPs were elevated in both SSc and
RP patients they were observed to have contrasting relationships with
small vessel digital perfusion. Further work is necessary to elucidate
the exact function of PMPs in these diseases. Such work would beneﬁt
from simultaneous investigation of EMPs given that theywere observed
to relate directly with perfusion in SSc but not RP suggesting the diverse
effects of EMPs between these two conditions. It is possible that the bal-
ance between EMPs and PMPs, rather than either MP subpopulation
alone, dictates digital perfusion with a rise in EMP numbers post cold
challenge potentially leading to improvements in digital perfusion.
Thus these results suggest that, not only may EMP and PMP measure-
ment act as a novel biomarker allowing prediction of disease progres-
sion, but also that MPs may serve as potential circulating biomarkers
of patients' underlying vascular health.Whilst further validation studies
are required, the observed relationship betweenMPs and vascular func-
tion suggests that MPs may be a simple non-invasive biomarker ofrimary Raynauds Phenomenon patients.
t 0 t 5 t 10 t 15
0.42 0.42 0.46 0.46
0.04 0.04 0.03 0.02
0.42 0.52 0.54 0.64
0.05 0.01 0.01 0.00
−0.33 −0.13 −0.39 0.09
0.2 0.65 0.13 0.75
−0.33 −0.69 −0.65 −0.49
0.23 0.00 0.00 0.06
n at the volar aspect of the distal left middle ﬁnger using Laser Speckle Contrast Imaging
d at baseline, immediately following cold challenge (t0) and at 5 min intervals during re-
21E.M. McCarthy et al. / BBA Clinical 7 (2017) 16–22vascular involvement across CTD. Future studies should evaluate the
sensitivity to change of MPs as biomarkers following therapeutic
intervention (e.g. immunosuppression, vasodilation and anti-platelet
therapies) across these disease groups.
4.1. Study limitations
Our study has a number of limitations. Whilst we have used a stan-
dard combination of markers to identify EMPs and PMPs (CD31 and
CD42b), others have used different combinations. Replication of our re-
sults using additional markers would add strength to our ﬁndings as
would elucidation and inclusion of Annexin V non-binding MPs. Simi-
larly the use of markers that identify both apoptotic and activated MPs
would allow formore detailed analysis of the phenotype ofMP involved
across the AIRDs assessed in this study. In addition, we acknowledge
that the patients with SSc recruited, were older than those with SLE, al-
though there was no difference in terms of disease duration. This is in
large part due to the different natural history of the diseases, with SLE
commonly presenting earlier. There appears to be very few, if any stud-
ies carried out on the impact of age on MP levels except in subjects
younger than 18 years old [24,25]. Finally due to a lack of availability
of all assessment instruments across sites SLE patientswere the only co-
hort in the study that had FMD measured whilst microvascular perfu-
sion following cold challengewasmeasured in SSc and RP patients only.
4.2. Future directions for study
Futureworkwould beneﬁt from includingbothmeasures of vascular
function in all those recruited to allow more precise interpretation and
analysis of the relative contribution of the tissue beds to microparticle
function. In addition larger replication studies are required, following
patients over time, which also allow for additional regression analysis
of the effects of environmental factors such as smoking etc. as well as
disease activity and patient characteristics across the diseases. Such a
study will also allow for the assessment of alteration in MP numbers
and phenotype with change in therapy and improved disease control.
Finally, additional functional experiments aimed at addressing the
exact role of EMPs and PMPs derived from SLE and SSc patients, as
well as the contributionof EMPs and PMPs derived fromdifferent vascu-
lar bed territories, are clearly required to determine the signiﬁcance of
the clinical observations we have identiﬁed.
Our study has found that the levels and relationship between EMPs
and PMPs differ across the spectrum of AIRDS, with high PMPs seen in
SSc/RP and high EMPs observed in SLE. The low EMP/PMP ratio in SSc/
primary RP, in comparison to SLE in particular, suggests differential re-
lease/production of MPs according to the background vascular patholo-
gy and vascular bed involved. The relationship between MPs and
vascular function also suggests that MPs may be a simple non-invasive
biomarker of vascular involvement across CTD andmay in the future as-
sist in establishing the degree of vascular disease modulation produced
by various therapeutic strategies.
Funding statement
This study was funded by Arthritis Research UK (18845) and the
Raynaud's and Scleroderma Association. This report includes indepen-
dent research supported by the National Institute for Health Research
Manchester Musculoskeletal Biomedical Research Unit. The views
expressed in this publication are those of the author(s) and not neces-
sarily those of the NHS, the National Institute for Health Research or
the Department of Health.
Conﬂict of interest
None of the authors has received any ﬁnancial support or other ben-
eﬁts from commercial sources for thework reported in this manuscript,nor do any of the authors have any other ﬁnancial interests which could
create a potential conﬂict of interest, or the appearance thereof.
Transparency Document
The Transparency document associated with this article can be
found, in the online version.References
[1] M. Diamant, M.E. Tushuizen, A. Sturk, R. Nieuwland, Cellular microparticles:
new players in the ﬁeld of vascular disease? Eur. J. Clin. Investig. 34 (6) (2004)
392–401.
[2] J.H. Distler, D.S. Pisetsky, L.C. Huber, J.R. Kalden, S. Gay, O. Distler, Microparticles as
regulators of inﬂammation: novel players of cellular crosstalk in the rheumatic dis-
eases, Arthritis Rheum. 52 (11) (2005) 3337–3348.
[3] L. Bernal-Mizrachi,W. Jy, J.J. Jimenez, J. Pastor, L.M. Mauro, L.L. Horstman, et al., High
levels of circulating endothelial microparticles in patients with acute coronary syn-
dromes, Am. Heart J. 145 (6) (2003) 962–970.
[4] H.A. Mostefai, F. Meziani, M.L. Mastronardi, A. Agouni, C. Heymes, C. Sargentini,
et al., Circulating microparticles from patients with septic shock exert protective
role in vascular function, Am. J. Respir. Crit. Care Med. 178 (11) (2008)
1148–1155.
[5] A.E. Berezin, A.A. Kremzer, Impaired phenotype of circulating endothelial micropar-
ticles in chronic heart failure patients: relevance to body mass index, Diabetol.
Metab. Syndr. 9 (4) (2015) 230–236.
[6] A.E. Berezin, A.A. Kremzer, T.A. Samura, T.A. Berezina, P. Kruzliak, Impaired im-
mune phenotype of circulating endothelial-derived microparticles in patients
with metabolic syndrome and diabetes mellitus, J. Endocrinol. Investig. 38 (8)
(2015) 865–874.
[7] S. Guiducci, J.H. Distler, A. Jungel, D. Huscher, L.C. Huber, B.A. Michel, et al.,
The relationship between plasma microparticles and disease mani-
festations in patients with systemic sclerosis, Arthritis Rheum. 58 (9) (2008)
2845–2853.
[8] E. Bartoloni, A. Alunno, O. Bistoni, S. Caterbi, F. Luccioli, G. Santoboni, et al., Charac-
terization of circulating endothelial microparticles and endothelial progenitor cells
in primary Sjogren's syndrome: newmarkers of chronic endothelial damage? Rheu-
matology (Oxford) 54 (3) (2015) 536–544.
[9] C.T. Nielsen, O. Ostergaard, C. Johnsen, S. Jacobsen, N.H. Heegaard, Distinct fea-
tures of circulating microparticles and their relationship to clinical manifesta-
tions in systemic lupus erythematosus, Arthritis Rheum. 63 (10) (2011)
3067–3077.
[10] R. Sgonc, M.S. Gruschwitz, H. Dietrich, H. Recheis, M.E. Gershwin, G. Wick, Endothe-
lial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian
and human scleroderma, J. Clin. Invest. 98 (3) (1996) 785–792.
[11] J.D. Pauling, V.B. O'Donnell, N.J. McHugh, The contribution of platelets to the patho-
genesis of Raynaud's phenomenon and systemic sclerosis, Platelets 24 (7) (2013)
503–515.
[12] L.V. Iversen, O. Ostergaard, S. Ullman, C.T. Nielsen, P. Halberg, T. Karlsmark, et al., Cir-
culating microparticles and plasma levels of soluble E- and P-selectins in patients
with systemic sclerosis, Scand. J. Rheumatol. 42 (6) (2013) 473–482.
[13] A.H. Lazarus, J. Ellis, J.W. Semple, M. Mody, A.R. Crow, J. Freedman, Comparison of
platelet immunity in patients with SLE and with ITP, Transfus. Sci. 22 (1–2)
(2000) 19–27.
[14] J. Pereira, G. Alfaro, M. Goycoolea, T. Quiroga, M. Ocqueteau, L. Massardo, et al., Cir-
culating platelet-derived microparticles in systemic lupus erythematosus. Associa-
tion with increased thrombin generation and procoagulant state, Thromb.
Haemost. 95 (1) (2006) 94–99.
[15] B. Parker, A. Al-Husain, P. Pemberton, A.P. Yates, P. Ho, R. Gorodkin, et al., Suppres-
sion of inﬂammation reduces endothelial microparticles in active systemic lupus er-
ythematosus, Ann. Rheum. Dis. 73 (6) (2014) 1144–1150.
[16] J.D. Pauling, J.A. Shipley, D.J. Hart, A. McGrogan, N.J. McHugh, Use of laser speckle
contrast imaging to assess digital microvascular function in Primary Raynaud phe-
nomenon and systemic sclerosis: a comparison using the Raynaud condition score
diary, J. Rheumatol. 42 (7) (2015) 1163–1168.
[17] Y. Miyazaki, S. Nomura, T. Miyake, H. Kagawa, C. Kitada, H. Taniguchi, et al., High
shear stress can initiate both platelet aggregation and shedding of procoagulant
containing microparticles, Blood 88 (9) (1996) 3456–3464.
[18] L.L. Horstman, W. Jy, J.J. Jimenez, Y.S. Ahn, Endothelial microparticles as markers of
endothelial dysfunction, Front. Biosci. 9 (2004) 1118–1135.
[19] J.J. Jimenez, W. Jy, L.M. Mauro, C. Soderland, L.L. Horstman, Y.S. Ahn, Endothelial cells
release phenotypically and quantitatively distinct microparticles in activation and
apoptosis, Thromb. Res. 109 (4) (2003) 175–180.
[20] D.B. Peterson, T. Sander, S. Kaul, B.T. Wakim, B. Halligan, S. Twigger, et al., Compar-
ative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles,
Proteomics 8 (12) (2008) 2430–2446.
[21] N. Mackman, G.E. Davis, Blood coagulation and blood vessel development: is tissue
factor the missing link? Arterioscler. Thromb. Vasc. Biol. 31 (11) (2011) 2364–2366.
[22] P.J. Yong, C.H. Koh,W.S. Shim, Endothelial microparticles: missing link in endothelial
dysfunction? Eur. J. Prev. Cardiol. 20 (3) (2013) 496–512.
[23] P.E. Rautou, A.S. Leroyer, B. Ramkhelawon, C. Devue, D. Duﬂaut, A.C. Vion, et al., Mi-
croparticles from human atherosclerotic plaques promote endothelial ICAM-1-
22 E.M. McCarthy et al. / BBA Clinical 7 (2017) 16–22dependent monocyte adhesion and transendothelial migration, Circ. Res. 108 (3)
(2011) 335–343.
[24] V. Proulle, B. Hugel, B. Guillet, L. Grunebaum, T. Lambert, J.M. Freyssinet, et al., Circu-
lating microparticles are elevated in haemophiliacs and non-haemophilic individ-
uals aged b18 years, Br. J. Haematol. 131 (4) (2005) 487–489.[25] J. Sellam, V. Proulle, A. Jungel, M. Ittah, C. Miceli Richard, J.E. Gottenberg, et al., In-
creased levels of circulating microparticles in primary Sjogren's syndrome, systemic
lupus erythematosus and rheumatoid arthritis and relation with disease activity, Ar-
thritis Res. Ther. 11 (5) (2009) R156.
